keyword
MENU ▼
Read by QxMD icon Read
search

bioresorbable vascular scaffold

keyword
https://www.readbyqxmd.com/read/28527768/randomized-comparison-of-absorb-bioresorbable-vascular-scaffold-and-mirage-microfiber-sirolimus-eluting-scaffold-using-multimodality-imaging
#1
Erhan Tenekecioglu, Patrick W Serruys, Yoshinobu Onuma, Ricardo Costa, Daniel Chamié, Yohei Sotomi, Ting-Bin Yu, Alexander Abizaid, Houng-Bang Liew, Teguh Santoso
OBJECTIVES: The primary objective of this study was to evaluate the safety and effectiveness of the Mirage bioresorbable microfiber sirolimus-eluting scaffold compared with the Absorb bioresorbable vascular scaffold in the treatment of stenotic target lesions located in native coronary arteries, ranging from ≥2.25 to ≤4.0 mm in diameter. Secondary objectives were to establish the medium-term safety, effectiveness, and performance of the Mirage device. BACKGROUND: The current generation of bioresorbable scaffolds has several limitations, such as thick square struts with large footprints that preclude their deep embedment into the vessel wall, resulting in protrusion into the lumen with microdisturbance of flow...
May 11, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28512285/coronary-aneurysm-formation-after-bioresorbable-vascular-scaffold-implantation-resulting-in-acute-myocardial-infarction
#2
Ching-Chang Fang, Yeun Tarl Fresner Ng Jao
BACKGROUND Development of a true coronary aneurysm after percutaneous coronary intervention is a rare event, and a coronary aneurysm resulting in acute myocardial infarction is even rarer. Coronary aneurysm formation after bioresorbable vascular scaffold (BVS) implantation, eventually leading to thrombosis, embolization, and myocardial infarction, has never been reported before in the literature. CASE REPORT A 62-year-old man received an elective BVS for a proximal left anterior descending lesion. Two months later, he suffered from a non-ST-segment myocardial infarction...
May 17, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28512068/potentially-increased-incidence-of-scaffold-thrombosis-in-patients-treated-with-absorb-bvs-who-terminated-dapt-before-18-months
#3
Cordula M Felix, Georgios J Vlachojannis, Alexander J J IJsselmuiden, Jiang M Fam, Peter C Smits, Wouter J Lansink, Roberto Diletti, Felix Zijlstra, Evelyn S Regar, Eric Boersma, Yoshinobu Onuma, Robert J M van Geuns
AIMS: The aim of this study was to investigate the impact of dual antiplatelet therapy (DAPT) termination on late and very late scaffold thrombosis (ScT) in patients treated with the Absorb bioresorbable vascular scaffold (BVS). METHODS AND RESULTS: Data from the registries of three centres were pooled (808 patients). To investigate the effect of DAPT termination on ScT after a minimum of six months, we selected a subgroup ("DAPT study cohort" with 685 patients) with known DAPT status >6 months and excluded the use of oral anticoagulants and early ScT...
May 18, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28504231/poland-coronary-and-structural-heart-interventions-from-2010-to-2015
#4
Jacek Legutko, Zbigniew Siudak, Radosław Parma, Andrzej Ochała, Dariusz Dudek
For the last five years, invasive cardiology in Poland has developed extensively. Currently, 98% of the 161 Polish cathlabs operate in 24/7 mode, 37 of them supported by cardiac surgery departments on-site. A certification curriculum for interventional cardiology operators is supported by dedicated workshops and scientific meetings during national conferences. The rise in the number of coronary angiographies and PCIs was paralleled by an increased use of drug-eluting stents, bioresorbable vascular scaffolds and physiologic assessment of coronary arteries...
May 15, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28504218/first-in-human-evaluation-of-a-novel-poly-l-lactide-based-sirolimus-eluting-bioresorbable-vascular-scaffold-for-the-treatment-of-de-novo-native-coronary-artery-lesions-meres-1-trial
#5
Ashok Seth, Yoshinobu Onuma, Ricardo Costa, Praveen Chandra, Vinay K Bahl, Cholenahally N Manjunath, Ajaykumar U Mahajan, Viveka Kumar, Pravin K Goel, Gurpreet S Wander, Mathew S Kalarickal, Upendra Kaul, V K Ajit Kumar, Pratap C Rath, Vijay Trehan, Gunasekaran Sengottuvelu, Sundeep Mishra, Alexandre Abizaid, Patrick W Serruys
AIMS: The MeRes-1 trial sought to study the safety and effectiveness of a novel sirolimus-eluting bioresorbable vascular scaffold (MeRes100 BRS) in treating de novo native coronary artery lesions by clinical evaluation and using multiple imaging modalities. METHODS AND RESULTS: The MeRes-1 first-in-human trial was a single-arm, prospective, multicentre study, which enrolled 108 patients with de novo coronary artery lesions (116 scaffolds were deployed to treat 116 lesions in 108 patients)...
May 16, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28500737/clinical-outcomes-of-overlapping-versus-non-overlapping-everolimus-eluting-absorb-bioresorbable-vascular-scaffolds-an-analysis-from-the-multicentre-prospective-rai-registry-clinicaltrials-gov-identifier-nct02298413
#6
Giuseppe Tarantini, Marco Mojoli, Giulia Masiero, Bernardo Cortese, Bruno Loi, Attilio Varricchio, Gabriele Gabrielli, Alessandro Durante, Giampaolo Pasquetto, Paolo Calabrò, Roberto Gistri, Gabriele Tumminello, Leonardo Misuraca, Francesco Pisano, Alfonso Ielasi, Pietro Mazzarotto, Sebastian Coscarelli, Valerio Lucci, Luciano Moretti, Annamaria Nicolino, Alessandro Colombo, Zoran Olivari, Massimo Fineschi, Davide Piraino, Luigi Piatti, Umberto Canosi, Paola Tellaroli, Donatella Corrado, Chiara Rovera, Giuseppe Steffenino
OBJECTIVES: To compare clinical outcomes of patients treated with overlapping versus non-overlapping Absorb BVS. BACKGROUND: Limited data are available on the clinical impact of stent overlap with the Absorb BVS bioresorbable stent. METHODS: We compared outcomes of patients receiving overlapping or non-overlapping Absorb BVS in the multicenter prospective RAI Registry. RESULTS: Out of 1,505 consecutive patients treated with Absorb BVS, 1,384 were eligible for this analysis...
May 13, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28476635/the-fate-of-incomplete-scaffold-apposition-of-everolimus-eluting-bioresorble-scaffolds-a-serial-optical-coherence-tomography-analysis
#7
Takao Sato, Ralph Tölg, Mohamed El-Mawardy, Dmitriy S Sulimov, Gert Richardt, Mohamed Abdel-Wahab
BACKGROUND: Incomplete stent apposition (ISA) can be divided into acute and late forms. Late ISA may be due to persistent ISA or late-acquired ISA (LAISA). This study evaluated the natural course of ISA after bioresorbable vascular scaffold (BRS) implantation using optical coherence tomography (OCT). METHODS: Thirty-two patients (45 BRS) were assessed immediately after BRS implantation and 1 year thereafter using OCT. Acute ISA identified after BRS implantation but absent at follow-up was defined as resolved; otherwise, it was considered persistent...
May 2, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28471557/insights-from-2d-and-3d-quantitative-angiographic-assessment-of-bioresorbable-everolimus-eluting-vascular-scaffolds
#8
Guy Witberg, Ifat Lavi, Hana Vaknin Assa, Katia Orvin, Abid Assali, Ran Kornowski
BACKGROUND: Bioresorbable vascular scaffold (BVS) is a promising technology that potentially offers several advantages over contemporary coronary drug-eluting stents (DES). Crucial to BVS implantation is the correct choice of scaffold size (diameter and length) in order to avoid "geographic miss" in length, provide the maximal support to the vessel wall, and avoid leaving "free-floating" foreign material in the coronary vasculature. OBJECTIVES: To assess the optimal method for measuring coronary stenosis prior to BVS implantation...
July 2016: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28471086/risk-and-timing-of-clinical-events-according-to-diabetic-status-of-patients-treated-with-everolimus-eluting-bioresorbable-vascular-scaffolds-versus-everolimus-eluting-stent-2-year-results-from-a-propensity-score-matched-comparison-of-absorb-extend-and-spirit
#9
Carlos M Campos, Adriano Caixeta, Marcelo Franken, Antonio L Bartorelli, Robert J Whitbourn, Chiung-Jen Wu, Hsien Li Paul Kao, Mohd Ali Rosli, Didier Carrie, Bernard De Bruyne, Gregg W Stone, Patrick W Serruys, Alexandre Abizaid
OBJECTIVES: to compare the occurrence of clinical events in diabetics treated with the Absorb bioresorbable vascular scaffold (Absorb BVS; Abbott Vascular, Santa Clara, CA) versus everolimus-eluting metal stents (EES; XIENCE V; Abbott Vascular, Santa Clara, CA) BACKGROUND: There are limited data dedicated to clinical outcomes of diabetic patients treated with bioresorbable scaffolds (BRS) at 2-year horizon. METHODS: The present study included 812 patients in the ABSORB EXTEND study in which a total of 215 diabetic patients were treated with Absorb BVS...
May 4, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28468954/long-term-efficacy-and-safety-of-everolimus-eluting-bioresorbable-vascular-scaffolds-versus-everolimus-eluting-metallic-stents-a-meta-analysis-of-randomized-trials
#10
Ahmed N Mahmoud, Amr F Barakat, Akram Y Elgendy, Erik Schneibel, Amgad Mentias, Ahmed Abuzaid, Islam Y Elgendy
BACKGROUND: Data regarding the long-term efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents are limited. This meta-analysis aimed to compare the long-term outcomes with both devices. METHODS AND RESULTS: Randomized trials reporting clinical outcomes beyond 1 year and comparing BVS with everolimus-eluting stents were included. Summary estimates risk ratios (RRs) were constructed. The primary efficacy outcome was target lesion failure, defined as cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization, and the primary safety outcome was definite or probable stent/scaffold thrombosis...
May 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28462904/evidence-of-acute-giant-cell-reaction-post-bioresorbable-vascular-scaffold-implantation
#11
Andrew D Mulligan, Cheng Yee Goh, Sarah Parsons, William Chan
No abstract text is available yet for this article.
May 2, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28461150/angina-and-ischemia-at-2-years-with-bioresorbable-vascular-scaffolds-and-metallic-drug-eluting-stents-estrofa-ischemia-bvs-mdes-study
#12
José M de la Torre Hernández, José R Rumoroso, Soledad Ojeda, Salvatore Brugaletta, José D Cascón, Cristina Ruisánchez, Joaquín Sánchez Gila, Jessica Roa, Helena Tizón, Hipólito Gutiérrez, Mariano Larman, Tamara García Camarero, Eduardo Pinar, José F Díaz, Manuel Pan, Miren Morillas Bueno, José M Oyonarte, Luis Ruiz Guerrero, Mireia Ble, Ramón Rubio Patón, Román Arnold, Kattalin Echegaray, Gonzalo de la Morena, Manel Sabate
INTRODUCTION AND OBJECTIVES: Bioresorbable vascular scaffolds (BVS) have the potential to restore vasomotion but the clinical implications are unknown. We sought to evaluate angina and ischemia in the long-term in patients treated with BVS and metallic drug-eluting stents (mDES). METHODS: Multicenter study including patients with 24 ± 6 months of uneventful follow-up, in which stress echocardiography was performed and functional status was assessed by the Seattle Angina Questionnaire (SAQ)...
April 28, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28438304/thirty-day-outcomes-after-unrestricted-implantation-of-bioresorbable-vascular-scaffold-from-the-prospective-rai-registry
#13
Bernardo Cortese, Alfonso Ielasi, Elisabetta Moscarella, Bruno Loi, Giuseppe Tarantini, Francesco Pisano, Alessandro Durante, Giampaolo Pasquetto, Alessandro Colombo, Gabriele Tumminello, Luciano Moretti, Paolo Calabrò, Pietro Mazzarotto, Attilio Varricchio, Maurizio Tespili, Roberto A Latini, Gianfranco Defilippi, Donatella Corrado, Giuseppe Steffenino
The Absorb biovascular scaffold (BVS) is a bioresorbable, everolimus-eluting scaffold whose data on real-world patients with complex lesions are limited. Short-term follow-up from recent studies point to a higher rate of 30-day thrombosis than observed with drug-eluting stents. We aimed to understand the short-term safety and efficacy of BVS. Registro Absorb Italiano (RAI, ClinicalTrials.gov:NCT02298413) is an Italian, prospective, multicenter registry not funded, whose aim is to investigate BVS performance through a 5-year follow-up of all consecutive patients who have undergone successful implantation of ≥1 BVS in different clinical/lesion subsets...
March 29, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28432385/bioresorbable-vascular-scaffolds-in-coronary-chronic-total-occlusions-revascularization-safety-assessment-related-to-struts-coverage-and-apposition-in-6-month-oct-follow-up
#14
Rosa Alba Abellas-Sequeiros, Raymundo Ocaranza-Sanchez, Ramiro Trillo-Nouche, Carlos Gonzalez-Juanatey, Jose Ramon Gonzalez-Juanatey
Beneficial properties of bioresorbable vascular scaffolds (BVS) regarding to vasomotility restoration and no caging of the vessel make them attractive devices in chronic total occlusions (CTO) revascularization. However, more evidence is needed attending to their use in this specific setting. We aim to determine feasibility and safety of BVS use in CTO revascularization attending to struts coverage and apposition, as well as re-stenosis and stent thrombosis (ST) rates. 29 BVS were deployed in 9 CTO lesions revascularization (mean J-CTO score ≥3) with an acute procedural success rate of 100%...
April 21, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/28430908/late-thrombotic-events-after-bioresorbable-scaffold-implantation-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#15
Carlos Collet, Taku Asano, Yosuke Miyazaki, Erhan Tenekecioglu, Yuki Katagiri, Yohei Sotomi, Rafael Cavalcante, Robbert J de Winter, Takeshi Kimura, Runlin Gao, Serban Puricel, Stéphane Cook, Davide Capodanno, Yoshinobu Onuma, Patrick W Serruys
Aims: To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions. Methods and Results: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp-Hartung method was used to compute odds ratios (OR) and 95% confidence intervals (CI)...
April 18, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28427596/bioresorbable-vascular-scaffolds-a-step-closer-to-the-dream
#16
EDITORIAL
Stephen Ellis
No abstract text is available yet for this article.
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28427595/vasomotor-response-to-nitroglycerine-over-5-years-follow-up-after-everolimus-eluting-bioresorbable-scaffold-implantation
#17
Dariusz Dudek, Łukasz Rzeszutko, Yoshinobu Onuma, Yohei Sotomi, Rafał Depukat, Susan Veldhof, Divine Ediebah, Peter Staehr, Wojciech Zasada, Krzysztof P Malinowski, Grzegorz L Kaluza, Patrick W Serruys
OBJECTIVES: This study investigated the vasomotor response to nitroglycerine (NTG) up to 5 years after ABSORB implantation. BACKGROUND: There are no data regarding long-term vasomotor response after everolimus-eluting bioresorbable vascular scaffold ABSORB implantation. METHODS: We performed quantitative coronary angiography of the scaffolded and proximal and distal adjacent segments of patients from ABSORB Cohort B study before and after 200 μg of intracoronary NTG at 2, 3, and 5 years of follow-up...
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28427593/economic-outcomes-of-bioresorbable%C3%A2-vascular-scaffolds-versus%C3%A2-everolimus-eluting-stents-in-patients%C3%A2-undergoing-percutaneous-coronary-intervention-1-year-results-from-the-absorb%C3%A2-iii-trial
#18
Suzanne J Baron, Yang Lei, Khaja Chinnakondepalli, Katherine Vilain, Elizabeth A Magnuson, Dean J Kereiakes, Stephen G Ellis, Gregg W Stone, David J Cohen
OBJECTIVES: The purpose of this study was to evaluate the economic impact of the Absorb bioresorbable vascular scaffold compared with the Xience everolimus-eluting stent in patients undergoing percutaneous coronary intervention. BACKGROUND: The ABSORB III trial (Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease) demonstrated that the Absorb scaffold was noninferior to the Xience stent with respect to target lesion failure at 1 year. Whether health care costs differ between the Absorb scaffold and the Xience stent is unknown...
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28424439/management-of-immediate-partial-bioresorbable-vascular-scaffold-stent-thrombosis
#19
Ziad Said Dahdouh, Bahaa M Fadel, Hani Al Sergani, Jehad Al Buraiki, Gilles Grollier
Bioresorbable vascular scaffold (BVS) stents have been proposed recently as an elegant technique for treatment of coronary artery disease. However, perspective that these "dissolvable" stents will replace conventional metallic stents in broad spectrum of clinical conditions and patient categories in the near future has been moderated by non-negligible incidence of stent thrombosis (ST). Mechanical factors, such as strut thickness and malapposition have been implicated in increased risk of BVS ST. Presently described is case of immediate partial BVS ST in a young male related to technical procedural problem, rather than mechanical problem...
March 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28421591/-full-plastic-jacket-reconstruction-of-18-cm-of-coronary-arteries-with-bioresorbable-vascular-scaffolds-in-a-young-patient-with-st-elevation-myocardial-infarction-and-multivessel-disease
#20
Andrea Denegri, Antonio Halais Frangieh, Fabrizio D'Ascenzo, Jelena Rima Ghadri, Fabian Nietlispach, Christian Templin
No abstract text is available yet for this article.
2017: Cardiology Journal
keyword
keyword
74350
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"